RELEASED
OpenAI releases GPT-Rosalind-6, its Astra-based life-sciences model, to approved research organisations only
2026-10-30
OpenAI published a safety report on October 30 for GPT-Rosalind-6, a new version of its life-sciences model for biology, drug discovery and translational medicine, and added it to the API changelog the same day. Access is tightly gated: GPT-6 Rosalind Research is available to approved research organisations through ChatGPT Work and Codex, API access needs a separate approval, and buying a subscription alone does not provide it. Applicants face a trusted-access review of their proposed research, security controls and governance, and in Enterprise workspaces the model starts with a two-week administrator preview, off by default.
The model uses the same underlying weights as GPT-6 Astra, with no additional training for this release. OpenAI says it refuses fewer legitimate biological questions that could also have harmful uses, while still refusing biological weaponisation. It is classified High capability in the biological and chemical domain and, relying on GPT-6 Astra's assessments, Critical in cybersecurity; none of its four Critical biological capability evaluations reached the relevant threshold.
On OpenAI's own benchmarks, at the highest reasoning budget tested, GPT-Rosalind-6 scored 49.6% on a medicinal-chemistry evaluation against 28.9% for GPT-Rosalind-5.5, 37.7% against 16.7% on genomics and quantitative biology, and 61.3% against 44.0% on an applied life-sciences benchmark built from tasks contributed by working scientists. OpenAI notes one biological-data benchmark used a configuration different from the production system, and the scores do not show the model can diagnose patients or deliver a successful medicine.